Intellia Therapeutics, Inc.
NTLA
$9.20
-$0.40-4.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.30% | 5.02% | 7.66% | -36.80% | 18.71% |
| Total Depreciation and Amortization | -2.65% | -1.61% | 0.35% | 3.46% | 1.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -44.54% | 2.01% | -32.25% | 304.36% | -58.28% |
| Change in Net Operating Assets | -2,981.57% | -79.48% | -66.44% | 199.65% | -1,055.85% |
| Cash from Operations | -74.81% | -0.42% | -45.80% | 51.78% | -29.67% |
| Capital Expenditure | 25.08% | 23.30% | -26.38% | 59.62% | -64.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -37.68% | 2,472.41% | 72.26% | -375.70% | -82.29% |
| Cash from Investing | -37.76% | 2,066.08% | 68.13% | -509.93% | -87.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -97.18% | 99.27% | -31.25% | -43.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -97.18% | 99.27% | -31.25% | -43.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -179.49% | 763.39% | 74.83% | 24.90% | -192.25% |